Testing mifomelatide to help maintain weight during chemo
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal or pancreatic cancer that cannot be surgically removed or has spread.
- You are about to receive your second round of specific chemotherapy regimens.
- You can eat and digest food normally, though a colostomy is okay.
- You are able and willing to give yourself a daily injection or have a caregiver do it.
- Your blood counts and organ function meet certain lab values (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking megestrol acetate (a medicine used to stimulate appetite and help gain weight) can reduce weight loss caused by chemotherapy in people with locally advanced colorectal cancer. It may help you maintain strength and energy during treatment.
This trial tests a new form of a drug (nano-megestrol acetate) to help people with advanced pancreatic cancer who are losing weight and have poor appetite. It aims to see if it can improve cachexia, a condition of severe weight loss and muscle wasting.
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
This trial tests a new drug called JMT203 for people with cancer-related weight loss (cachexia). It aims to see if the drug can help prevent or reverse weight loss in patients with certain solid tumors who are also receiving or have recently completed anti-cancer therapy.
This Phase 3 trial compares a new treatment combination (chidamide plus sintilimab plus bevacizumab) versus the standard second-line chemotherapy (FOLFIRI plus bevacizumab) for advanced colorectal cancer that is microsatellite stable/low. It aims to see which treatment works better and is safer for people whose cancer grew after first-line oxaliplatin-based therapy.
This trial tests a weight management program for women with early-stage endometrial cancer or atypical hyperplasia who want to keep their fertility. It aims to see if losing weight can improve treatment outcomes.
Hear when a new Cancer Weight Loss trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.